Lisa A. Carey, MD, of the University of North Carolina, and Sibylle Loibl, MD, PhD, of the German Breast Group, discuss new data on palbociclib, new immunotherapy, and brain metastases (Abstract YR4).
Andrew Seidman, MD, of Memorial Sloan Kettering Cancer Center, and Sabine Siesling, PhD, of the Netherlands Comprehensive Cancer Organization, discuss the improved overall survival after 10 years in women who received breast-conserving surgery compared with those who received mastectomy with radiation treatment. (Abstract S3-05)
Andrew Seidman, MD, of Memorial Sloan Kettering Cancer Center, and Hope S. Rugo, MD, of the University of California, San Francisco, discuss preliminary efficacy and safety findings of pembrolizumab in patients with PD-L1–positive, estrogen receptor-positive/HER2-negative disease. (Abstract S5-07)
Hans Wildiers, MD, PhD, of the University Hospitals, Leuven, discusses this phase III study on the use of ado-trastuzumab emtansine vs treatment of physician’s choice in previously treated HER2-positive metastatic breast cancer (Abstract S5-05).
Sarat Chandarlapaty, MD, PhD, of the Memorial Sloan Kettering Cancer Center, discusses results from this study that showed patients with ER-positive metastatic breast cancer who had a D538G and/or a Y537S mutation in the ESR1 gene had significantly worse median overall survival (Abstract S2-07).
Sherene Loi, MD, of Peter MacCallum Cancer Centre, discusses a pooled individual patient data analysis of stromal tumor-infiltrating lymphocytes in primary triple-negative breast cancer treated with anthracycline-based chemotherapy (Abstract S1-03).
